Feasibility Study on Establishing Biomarkers in Lung Diseases

Biomarker in Lung Diseases

Sponsors

Lead sponsor: Heidelberg University

Source Heidelberg University
Brief Summary

Disease related biomarkers have been established decades ago, e.g. blood glucose for diabetes diagnosis and management. Their discovery has grown dramatically during the past decade and they have the potential to lead the physician in diagnosis -especially differential diagnosis - and therapy.

However, a specific serum-biomarker in lung diseases has not been established. Aim of the current study is to to measure lung specific proteins in the serum in patients with various lung diseases and to correlate those with disease severity, lung function and other laboratory results

Overall Status Unknown status
Start Date October 2009
Completion Date June 2010
Primary Completion Date March 2010
Study Type Observational
Primary Outcome
Measure Time Frame
Serum biomarker expression 1 month
Enrollment 120
Condition
Intervention

Intervention type: Other

Intervention name: biomarker

Description: measuring serum-biomarkers

Arm group label: lung disease

Eligibility

Sampling method: Non-Probability Sample

Criteria:

Inclusion Criteria:

- age >= 18

- acute or chronic lung disease

Exclusion Criteria:

- HIV

- lactation or gestation

Gender: All

Minimum age: 18 Years

Maximum age: 90 Years

Healthy volunteers: No

Overall Official
Overall Contact

Last name: Michael Kreuter, MD

Phone: 49 / 6221 / 396

Phone ext: 1201

Email: [email protected]

Location
facility status contact investigator Thoraxklinik Heidelberg, Dept. of Pneumology and Respiratory Critical care Michael Kreuter, MD 49 / 6221 / 396 1201 [email protected] Michael Kreuter, MD Principal Investigator
Location Countries

Germany

Verification Date

October 2009

Responsible Party

Name title: Dr. Michael Kreuter

Organization: Thoraxklinik Heidelberg

Keywords
Has Expanded Access No
Condition Browse
Arm Group

Arm group label: lung disease

Description: patients with various chronic or acute lung diseases

Study Design Info

Observational model: Cohort

Time perspective: Prospective

Source: ClinicalTrials.gov